Longevity Biomedical (Longevity Biomedical) Debt-to-Asset : 0.00 (As of . 20)

View and export this data going back to 2050. Start your Free Trial

What is Longevity Biomedical Debt-to-Asset?

Longevity Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in . 20 was $0.00 Mil.

Longevity Biomedical Debt-to-Asset Historical Data

The historical data trend for Longevity Biomedical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longevity Biomedical Debt-to-Asset Chart

Longevity Biomedical Annual Data

Trend

Debt-to-Asset

Longevity Biomedical Semi-Annual Data

Debt-to-Asset

Competitive Comparison of Longevity Biomedical's Debt-to-Asset

For the Biotechnology subindustry, Longevity Biomedical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Debt-to-Asset falls into.

Longevity Biomedical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Longevity Biomedical's Debt-to-Asset for the fiscal year that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Longevity Biomedical's Debt-to-Asset for the quarter that ended in . 20 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(	+	)	/
	=	N/A

Longevity Biomedical (NAS:LBIO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Longevity Biomedical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Longevity Biomedical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Longevity Biomedical (Longevity Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longevity Biomedical Inc (NAS:LBIO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011

Website

https://www.longevitybiomedical.com

Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.

Longevity Biomedical (Longevity Biomedical) Headlines

No Headlines